ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,899Medicare Part D Prescriptions Filled, Including Refills

Rank: 56 out of 393

$676K Total Retail Price of All Prescriptions

Rank: 28 out of 393

584 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
75% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 584 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

13% of this provider’s 584 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 7,527 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
AMLODIPINE BESYLATE 717 643 1 4
SIMVASTATIN 646 531 2 1
METFORMIN HCL 425 323 3 7
OMEPRAZOLE 290 245 4 6
LISINOPRIL 267 217 5 2
HYDROCODONE-ACETAMINOPHEN 234 98 S3 6 5
LOSARTAN POTASSIUM 233 192 7 12
METOPROLOL TARTRATE 231 202 8 9
ALENDRONATE SODIUM 191 180 9 16
AMOX TR-POTASSIUM CLAVULANATE 186 132 10 100
GABAPENTIN 184 134 11 15
ZOLPIDEM TARTRATE 178 68 12 11
ALLOPURINOL 150 120 13 26
LEVOTHYROXINE SODIUM 150 129 13 3
GLIPIZIDE 124 96 15 32
NEXIUM 122 83 16 84
ATENOLOL 111 83 17 13
LOVASTATIN 110 94 18 14
CARVEDILOL 110 88 18 21
ADVAIR DISKUS 108 75 20 53
DIOVAN 107 99 21 69
FUROSEMIDE 103 63 22 8
CLOPIDOGREL 95 89 23 33
ATORVASTATIN CALCIUM 89 82 24 19
OXYCODONE HCL 89 0 S2 24 36
PLAVIX 88 82 26 51
TRAMADOL HCL 86 80 27 30
AZITHROMYCIN 77 66 28 35
JANUVIA 75 62 29 87
SPIRIVA 72 46 30 41
RANITIDINE HCL 72 62 30 29
FAMOTIDINE 70 61 32 70
CLOBETASOL PROPIONATE 70 56 32 188
IBUPROFEN 69 52 34 55
WARFARIN SODIUM 68 47 35 17
METOPROLOL SUCCINATE 67 62 36 22
TAMSULOSIN HCL 66 64 37 25
CARISOPRODOL 65 0 R 38 45
DONEPEZIL HCL 65 58 38 34
METHYLPREDNISOLONE 64 51 40 80
LISINOPRIL-HYDROCHLOROTHIAZIDE 63 35 41 24
LOSARTAN-HYDROCHLOROTHIAZIDE 59 53 42 31
POTASSIUM CHLORIDE 57 37 43 20
PANTOPRAZOLE SODIUM 57 49 43 56
GLIMEPIRIDE 56 46 45 39
DIGOXIN 55 27 46 66
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 27, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.